Q2 Q2 Q2

Q2 earnings preview, biotechnology breakout

Equities 10 minutes to read
PG
Peter Garnry

Head of Equity Strategy

Summary:  The Q2 earnings season starts next week and will run at full speed during the rest of July and first half of August. We focus on the most important earnings releases over the coming three weeks and explain what to watch in each report. One thing is certain, companies with margin power will be rewarded by the market. Finally, we put a perspective on the recent 25% rally in our NextGen Medicine theme basket highlighting that the industry is fragile as long as financial conditions continue to tighten.


Q2 earnings are all about margin power or not

The Q2 earnings season starts next week and we recently wrote an earnings preview focusing on rosy expectations ahead of Q2 earnings and that the energy sector would continue to shine. The overall theme this season is margin pressure (see chart) and companies that can surprise to the upside on operating margin will be rewarded by the market. In our view the outlook from companies will be so uncertain that it will be difficult for Q2 earnings to materially lift the equity market as the FOMC rate hike in July and tighter financial conditions will likely overshadow earnings. In any case, companies with margin power are the winners of the market during the Q2 earnings season.

The equity desk will be running low in July due to holiday but of all the major earnings expected over the next three weeks the following ones are the most important one to watch.

  • JPMorgan Chase: US banks have not reacted positively on rising US interest rates since November last year as the market is expecting a muted increase in the net interest margin, which is likely offset by falling activity from the consumer across mortgages and card spending. Higher credit provisions are also likely given the tighter financial conditions.

  • Lockheed Martin: US defence stocks have not moved much compared to their European competitors since the war in Ukraine broke out. While Europe will prioritise their own defence industry the increased spending will also flow to US defence companies and Lockheed Martin’s Q2 earnings release will give the first hint if that is indeed the case.

  • Netflix: the world’s largest online streaming service is seeing a user decline, increased competition, increased costs for content production, and customers are generally hit by the cost-of-living crisis. Investors will focus on whether the company will announce a new ads-based tiering model to lower entry costs for streaming for those households hit the hardest by inflation.

  • Halliburton: the oil and gas industry is still reluctant about investing too much in new oil and gas fields due to the political pressures against fossil fuels. Halliburton is a big oil services company and will see the pick up in capital expenditures in the oil industry.

  • Tesla: Covid lockdowns in China have severely constrained the EV-maker in Q2 with deliveries falling q/q for the first time in more than two years. At the same time, the EV-maker has production difficulties at its factories in Texas and Germany, and competition is heating up from most notably Volkswagen and BYD.

  • ASML: several semiconductor manufacturers such as Micron and Samsung have recently issued gloomy outlooks and these forecasts could also dent the outlook of ASML which delivers semiconductor equipment. The company has also recently been pressured by the US to halt sales to China of certain equipment.

  • ABB: with the galloping energy crisis in Europe industrials are under pressure as industrial activity is difficult at punitive electricity prices. A general slowdown in the global economy could also negatively impact the outlook.

  • Alphabet: since Q1 earnings Snap has been out cutting its revenue growth guidance on weaker advertising demand, but Alphabet has not done this. However, there is a lot of evidence that businesses are cutting down on marketing expenses to offset the pressure on operating margin. Outside the advertising business we expect the cloud computing division to still doing well.

  • Microsoft: steady as a ship as the company is still running a near monopoly globally in computer operating systems and its cloud business is winning market share. Business spending has not taken a hit yet but Samsung said yesterday that they are beginning to see that so this might be a risk factor going into Microsoft earnings.

  • Meta: same story as Alphabet, but with a caveat. Meta is spending $3bn per quarter on its new Metaverse bet and investors might be running out of patience with Mark Zuckerberg’s ambitions to create a new computing platform for the future. Especially, if the advertising business continues to lose momentum over the data privacy change that Apple made on its iPhones making it more difficult for Meta to deliver efficient ads.

  • Apple: being a high-end consumer electronics maker Apple could be faced with bigger headwinds from inflation than what the market is currently betting on. Samsung’s outlook was ignored by Apple investors but that might come back and haunt them when Apple releases earnings. Supply chain constraints are also a critical issue for Apple which could lead to a negative revenue growth surprise.

  • Amazon: the ‘everything store’ overspent during the pandemic and is being pressured on operating margins from higher fulfillment and logistics costs. In its cloud computing division Microsoft and Google are also adding more pressure. There is a lot of pressure on the new CEO to restore operating margin in its e-commerce business.

The most important earnings releases the next three weeks are listed below. Please note that some of these earnings dates might be moved after this publication.

  • Tuesday 12 July: Tryg, DNB Bank, PepsiCo
  • Wednesday 13 July: Fastenal, Delta Air Lines
  • Thursday 14 July: Fast Retailing, Ericsson, SEB, EQT, JPMorgan Chase, Morgan Stanley, Cintas
  • Friday 15 July: Investor, Sandvik, EMS-Chemie, UnitedHealth, Wells Fargo, Charles Schwab, BlackRock, Citigroup, Progressive, US Bancorp, PNC Financial Services
  • Monday 18 July: Bank of America, IBM, Goldman Sachs, Nordea
  • Tuesday 19 July: Johnson & Johnson, Novartis, Lockheed Martin, Netflix, Atlas Copco, Volvo, Halliburton, Assa Abloy, Hasbro, Yara International
  • Wednesday 20 July: Tesla, Abbott Laboratories, ASML, CSX, Nidex, Biogen, Baker Hughes, Kone, Volvo Car, Aker, Dassault Aviation, United Airlines, ASM International, Alfa Laval
  • Thursday 21 July: Roche, Danaher, AT&T, Blackstone, SAP, Intuitive Surgical, ABB, Freeport-McMoRan, Kinder Morgan, Nucor, DR Horton, Nokia, Essity, Seagate Technology, MarketAxess
  • Friday 22 July: Verizon, NextEra Energy, American Express, Schlumberger, Twitter, Danske Bank, Norsk Hydro
  • Monday 25 July: NXP Semiconductors, Kuehne + Nagel, Philips, Ryanair
  • Tuesday 26 July: Alphabet, Visa, LVMH, Coca-Cola, McDonald’s, UPS, Texas Instruments, Raytheon Technologies, Unilever, Christian Dior, General Electric, UBS Group, General Motors, Archer-Daniels-Midland, Southern Copper, DSV, UniCredit
  • Wednesday 27 July: Microsoft, Meta, Bristol-Myers Squibb, Qualcomm, AMD, Equinor, GSK, ServiceNow, Rio Tinto, Mondelez, Boeing, Airbus, 3M, Kering, Humana, Mercedes-Benz, Ford Motor, Kraft Heinz, Shopify, BASF, Danone, Fanucm Enphase Energy, Spotify, Garmin
  • Thursday 28 July: Apple, Nestle, Pfizer, Merck, L’Oreal, Shell, Comcast, Intel, Linde, TotalEnergies, Sanofi, Honeywell, Anheuser-Busch InBev, Keyence, Volkswagen, Air Liquide, Schneider Electric, Banco Santander, Valero Energy, Stellantis, Neste, BAE Systems, Arcelor Mittal
  • Friday 29 July: Amazon, Exxon Mobil, P&G, Mastercard, Chevron, AbbVie, AstraZeneca, Sony, Caterpillar, Colgate-Palmolive, BNP Paribas, Twilio, Pinterest

Biotechnology rebound rally at odds with financial conditions

Our NextGen Medicine basket which is reflecting a large part of the innovative biotechnology industry is up 25% from the recent lows rallying on a combination of easing inflation and interest rates expectations, and potentially short covering. This part of the equity market has the absolute highest duration (sensitivity to interest rates) as many of these companies are many years from break-even because many of them have high equity valuations and are most research-driven companies.

While biotechnology stocks have rebounded recently we remain cautious on the industry over the next six months as financial conditions continue to tighten (see chart) and the current levels and direction will continue to negatively impact financing for these companies which is a necessary feature of the industry to fund their drug research activities.

NextGen Medicine basket vs MSCI World Index | Source: Bloomberg
US financial conditions | Source: Bloomberg
Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo Capital Markets HK Limited holds a Type 1 Regulated Activity (Dealing in securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged foreign exchange trading); Type 4 Regulated Activity (Advising on securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong

By clicking on certain links on this site, you are aware and agree to leave the website of Saxo Capital Markets, proceed on to the linked site managed by Saxo Group and where you will be subject to the terms of that linked site.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

Please note that the information on this site and any product and services we offer are not targeted at investors residing in the United States and Japan, and are not intended for distribution to, or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. Please click here to view our full disclaimer.